Stocks on the Move: TPIV, INO, MBCI, CRXL
05 Novembre 2009 - 2:18PM
Marketwired
TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing
in the development of immunotherapeutic vaccines for cancer and
infectious diseases, has signed a license agreement with Crucell
N.V (NASDAQ: CRXL).
Terms of the agreement allow TapImmune to use the proprietary
PER.C6® cells in its development programs. The PER.C6® cell line is
suited for the development and large-scale manufacturing of a
multitude of biopharmaceuticals. In the use of recombinant vaccines
using adenoviral vectors, PER.C6® cells do not generate replication
competent adenoviruses, making it the state-of-the-art platform for
the large-scale production of adenoviral vectors for clinical
applications.
Inovio Biomedical Corporation (AMEX: INO) engages in the design,
development, and delivery of a new generation of vaccines, called
DNA vaccines rose almost 4% for the week.
Yesterday, MabCure N.V, a subsidiary of MabCure Inc. (OTCBB:
MBCI), announced the signing of a research agreement with AZ Sint
Lucas Hospital, Brugge, Belgium, to conduct preclinical research on
its Monoclonal Antibodies (Mabs) against different cancers.
About Smallcap-Investors.com
Smallcap-Investors.com.com is a leading investor relations firm
whose primary focus is promoting awareness among brokers,
investors, and others in the investment community who are
interested in small and micro-cap companies. Smallcap-Investors
goal is to feature equity investments in micro or small
capitalization companies that have the potential for long-term
appreciation. Smallcap-Investors.com offers a free financial
newsletter. To subscribe or get more information, visit our home
page located at www.Smallcap-Investors.com. An affiliate of
Smallcap-Investors.com has been promised compensation by TapImmune
Inc. for the dissemination of this Press Release.
CONTACT: www.Smallcap-Investors.com Email Contact
561-909-0139
Grafico Azioni MabCure (CE) (USOTC:MBCI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni MabCure (CE) (USOTC:MBCI)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a MabCure Inc (CE) (OTCMarkets): 0 articoli recenti
Più Smallcap-Investors Articoli Notizie